|
Sample name
|
Raw data
|
Valid data
|
Efficient(reads)%
|
Q20 %
|
Q30 %
|
GC content%
|
|---|
|
Read
|
Base
|
Read
|
Base
|
|---|
|
FCA1
|
54,383,990
|
8.16G
|
53,835,634
|
8.08G
|
98.99
|
99.58
|
95.01
|
51.50
|
|
FCA2
|
41,050,214
|
6.16G
|
40,649,424
|
6.10G
|
99.02
|
99.77
|
96.14
|
52.00
|
|
FCA3
|
40,700,236
|
6.11G
|
40,326,736
|
6.05G
|
99.08
|
99.76
|
95.82
|
51.50
|
|
AT10_1
|
40,741,106
|
6.11G
|
40,307,186
|
6.05G
|
98.93
|
99.60
|
95.16
|
51.00
|
|
AT10_2
|
57,742,958
|
8.66G
|
57,142,398
|
8.57G
|
98.96
|
99.42
|
92.66
|
50.50
|
|
AT10_3
|
51,520,986
|
7.73G
|
50,998,720
|
7.65G
|
98.99
|
99.62
|
93.96
|
50.50
|
|
AT1_1
|
54,593,420
|
8.19G
|
54,067,912
|
8.11G
|
99.04
|
99.60
|
93.56
|
51.00
|
|
AT1_2
|
46,452,368
|
6.97G
|
46,050,198
|
6.91G
|
99.13
|
99.63
|
93.87
|
51.50
|
|
AT1_3
|
50,198,580
|
7.53G
|
49,764,940
|
7.46G
|
99.14
|
99.32
|
91.97
|
51.00
|
|
AT01_1
|
56,340,820
|
8.45G
|
55,884,918
|
8.38G
|
99.19
|
99.38
|
92.94
|
52.50
|
|
AT01_2
|
52,741,640
|
7.91G
|
52,255,040
|
7.84G
|
99.08
|
99.58
|
94.17
|
51.50
|
|
AT01_3
|
85,115,910
|
12.77G
|
84,203,182
|
12.63G
|
98.93
|
99.58
|
94.00
|
50.50
|
- In the experimental design, the AA rat FLS group was represented as FCA groups in the Table 1; AA rat FLS + TCDCA high dose treatment was represented as AT10 group; AA rat FLS + TCDCA medium dose treatment was represented as AT1 group; AA rat FLS + TCDCA low dose treatment was represented as AT01 group; The numbers 1, 2, and 3 represented three sets of repeated studies
